Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: DV reports personal fees from Bayer, outside the submitted work, and full-time employment at Bayer. AG reports personal fees from Regeneron Pharmaceuticals, outside the submitted work; and she a full-time employee at Regeneron Pharmaceuticals. GH reports grants from US National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work. AS reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. SF is an employee of Janssen, Research and Development, a subsidiary of Johnson & Johnson. PR is an employee of Janssen Research and Development and shareholder of Johnson & Johnson. KK and CR report being employees of IQVIA. MS reports grants from US National Institutes of Health, grants from Department of Veterans Affairs, during the conduct of the study; grants from IQVIA, personal fees from Janssen Research and Development, outside the submitted work. DPA reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA's department and open for external participants. FN was an employee of AstraZeneca until 2019 and holds some AstraZeneca shares. The views expressed are those of the authors and do not necessarily represent the views or policy of the Department of Veterans Affairs or the United States Government. No other relationships or activities that could appear to have influenced the submitted work.

Funding Statement

The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257). The IDIAPJGol received funding from the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direccio General de Recerca i Innovacio en Salut. DPA received funding from the NIHR Academy in the form of an NIHR Senior Research Fellowship. WURA reports funding from the NIHR Oxford Biomedical Research Centre (BRC), Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England. No funders had a direct role in this study. DRM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z). The views and opinions expressed are those of the authors and do not necessarily reflect those of the NIHR Academy, NIHR, Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All the data partners received Institutional Review Board (IRB) approval or exemption. STARR-OMOP had approval from IRB Panel #8 (RB-53248) registered to Leland Stanford Junior University under the Stanford Human Research Protection Program (HRPP). The use of VA data was reviewed by the Department of Veterans Affairs Central IRB, was determined to meet the criteria for exemption under Exemption Category 4(3), and approved for Waiver of HIPAA Authorization. The IRB number for use of HIRA data was AJIB-MED-EXP20-065. The research was approved by the Columbia University Institutional Review Board as an OHDSI network study. The use of SIDIAP was approved by the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/070-PCV). The use of CPRD was approved by the Independent Scientific Advisory Committee (ISAC) (protocol number 20_059RA2). The use of IQVIA-OpenClaims, IQVIA-LPD-France, and IQVIA-DA-Germany were exempted from IRB approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes